VANCOUVER, British Columbia, Aug. 16, 2007 (PRIME NEWSWIRE) -- TapImmune Inc. (OTCBB:TPIM) (Germany:GX1A), a biotechnology company specializing in the development of immunotherapeutics for cancer and vaccines for infectious diseases, today announced a contractual agreement with AppTec, headquartered in St. Paul, Minnesota, for the preclinical testing of its lead product. The immunotherapy vaccine is designed to treat a wide variety of carcinomas that include lung cancers, liver cancers, kidney cancers, head and neck cancers, breast cancers, melanomas, prostate cancers, colorectal cancers, and cervical cancers. This is the first stage in moving the Company's proprietary vaccine from the research laboratory into clinical investigation.
Once AppTec certifies the vaccine as sterile and free of contamination, TapImmune will move forward with the production of commercial grade vaccine in FDA approved facilities to commence pre-clinical work, toxicology and Phase I clinical trials.
"This partnership signifies the first step on our clinical critical path," said Denis Corin, CEO and President of TapImmune Inc. "Moving our product from the research laboratory and into FDA regulated facilities for testing signifies our commitment to advance this research and bring to market a product which we believe will have a significant impact on the battle against cancer."
"AppTec is very pleased that TapImmune has chosen to partner with us in this next phase of development for their new vaccine," said Bonnie Baskin, CEO of AppTec, "and we are excited to play a role in helping to advance such an important product closer to market."
About AppTec
AppTec offers comprehensive testing, contract research and development, and cGMP manufacturing services for biopharmaceuticals, medical devices, cellular therapeutics and tissue-based products from a unique single-source platform. The company has three facilities -- St. Paul, MN (also the corporate headquarters); Philadelphia, PA; and Atlanta, GA -- all of which are GLP and cGMP compliant and FDA registered. For more than 20 years, AppTec has served the biopharmaceutical/biotechnology and medical device/medical product industries in their efforts to bring products to market faster while meeting regulatory guidelines worldwide.
About TapImmune Inc.
TapImmune Inc. is a biotechnology company specializing in the development of innovative therapeutics and vaccines in the areas of oncology and infectious disease. The company's lead product, the AdhTAP vaccine restores and augments antigen presentation and subsequent recognition and killing of cancer cells by the immune system. The company is currently developing AdhTAP for the commencement of toxicology studies leading to the initiation of a Phase I clinical trial. The Company is also developing a TAP based vaccine adjuvant already proven to increase the efficacy of targeted prophylactic vaccines by up to 1,000 times.
The TapImmune Inc. logo is available at http://www.primenewswire.com/newsroom/prs/?pkgid=3877
Forward-Looking Statement Disclaimer
This release contains forward-looking information within the meaning of the Private Securities Litigation Reform Act of 1995. Statements in this news release concerning the Company's expectations, plans, business outlook or future performance, and any other statements concerning assumptions made or expectations as to any future events, conditions, performance or other matters, are "forward-looking statements." Forward-looking statements are by their nature subject to risks, uncertainties and other factors which could cause actual results to differ materially from those stored in such statements. Such risks, uncertainties and factors include, but are not limited to the risks set forth in the Company's most recent Form 10-KSB and other SEC filings which are available through EDGAR at www.sec.gov. These are among the primary risks we foresee at the present time. The Company assumes no obligation to update the forward-looking statements.